Therapy Detail

Therapy Name JQ1
Therapy Description

JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression and cell death (PMID: 24231268).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
JQ1 BET Inhibitor (Pan) 25 JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression and cell death (PMID: 24231268).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO I408V Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
Unknown unknown Ewing sarcoma not applicable JQ1 Preclinical - Pdx & cell culture Actionable In a preclinical study, JQ1 treatment resulted in cytostatic effects in patient-derived Ewing's sarcoma cell lines in culture, but inhibited tumor growth in patient-derived xenograft models due to inhibition of tumor angiogenesis (PMID: 26908627). 26908627
SMO V321M Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
ARID1A loss ovarian clear cell carcinoma predicted - sensitive JQ1 Preclinical - Cell culture Actionable In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405). 29760405
ARID1A Q1148* ovarian clear cell carcinoma predicted - sensitive JQ1 Preclinical - Pdx Actionable In a preclinical study, JQ1 inhibited tumor growth in an ovarian clear cell carcinoma patient-derived xenograft (PDX) model harboring ARID1A Q1148*, but did not inhibit growth in a model with wild-type ARID1A (PMID: 29760405). 29760405
TP53 mutant medulloblastoma decreased response JQ1 Preclinical Actionable In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268). 24231268
Unknown unknown triple-receptor negative breast cancer not applicable JQ1 Preclinical - Cell line xenograft Actionable In a preclinical study, triple-receptor negative breast cancer cells demonstrated sensitivity to treatment with JQ1, resulting in decrease cell proliferation and cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 27256375). 27256375
SMO T241M Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
TP53 wild-type medulloblastoma sensitive JQ1 Preclinical Actionable In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268). 24231268
Unknown unknown pancreatic ductal adenocarcinoma not applicable JQ1 Preclinical - Pdx & cell culture Actionable In a preclinical study, treatment with JQ1 in patient derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC) demonstrated tumor growth suppression and in PDAC cells, resulted in inhibition of Hedgehog and TGF-beta signaling and a decrease in desmoplastic stroma (PMID: 27528027). 27528027
Unknown unknown rhabdomyosarcoma not applicable JQ1 Preclinical - Pdx & cell culture Actionable In a preclinical study, JQ1 treatment resulted in cytostatic effects in patient-derived rhabdomyosarcoma cell lines in culture, but inhibited tumor growth in patient-derived xenograft models due to inhibition of tumor angiogenesis (PMID: 26908627). 26908627
SMO A459V Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
SMO C469Y Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
SMO W281C Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
Clinical Trial Phase Therapies Title Recruitment Status